Email this article 
THE EVALUATION OF EFFICIENCY OF REORGANIZATION OF MEDICAL CARE UNDER DISSEMINATED SCLEROSIS ON THE BASIS OF ANALYSIS OF DYNAMICS OF TREATMENT WITH MEDICATIONS ALTERING COURSE OF DISSEMINATED SCLEROSIS
- Authors: Cherepianskii M.S.1, Baranov A.V.2, Penina G.O.2
- Affiliations:
- The State Budgetary Institution of the Komi Republic "The Komi Republic Clinical Hospital", 167004, Syktyvkar, Russia
- The Federal State Budgetary Educational Institution of Higher Education "The Pitirim Sorokin Syktyvkar State University", 167001, Syktyvkar, Russia
- Issue: Vol 34, No 3 (2026)
- Pages: 620-625
- Section: Articles
- URL: https://journal-nriph.ru/journal/article/view/2703
- DOI: https://doi.org/10.32687/0869-866X-2026-34-3-620-625
- Cite item
Abstract
The multiple sclerosis is chronic autoimmune disease with high risk of disability. The effective management of this disease directly depends on the timely prescription and escalation of treatment with medications altering course of multiple sclerosis. The key factor in optimizing medical care is organization of specialized structures. The specialized Multiple Sclerosis Clinic was opened in the Komi Republic in the beginning of 2021. The purpose of the study is to assess dynamics of key indicators of medication therapy of multiple sclerosis during 2018–2024 and to determine impact of opening of Multiple Sclerosis Clinic on these indicators using methods of statistical analysis.
About the authors
M. S. Cherepianskii
The State Budgetary Institution of the Komi Republic "The Komi Republic Clinical Hospital", 167004, Syktyvkar, Russia
A. V. Baranov
The Federal State Budgetary Educational Institution of Higher Education "The Pitirim Sorokin Syktyvkar State University", 167001, Syktyvkar, Russia
G. O. Penina
The Federal State Budgetary Educational Institution of Higher Education "The Pitirim Sorokin Syktyvkar State University", 167001, Syktyvkar, Russia
References
- Сороковикова Т. В., Морозов А. М., Крюкова А. Н., Наумова С. А., Беляк М. А. Перспективы лечения прогрессирующих форм рассеяного склероза трасплантацией стволовых клеток (обзор литературы). Вестник медицинского института "РЕАВИЗ". Реабилитация, Врач и Здоровье. 2023;13(4):154—61. doi: 10.20340/vmi-rvz.2023.4.TX.3
- Bayas A., Christ M., Faissner S. Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis — a review of population-specific evidence from randomized clinical trials. Ther. Adv. Neurol. Disord. 2023;16:17562864221146836.. doi: 10.1177/17562864221146836
- Robinson W. El., Steinman L. Epstein-Barr virus and multiple sclerosis. Science. 2022;375(6578):264—5. doi: 10.1126/science.abm7930
- Govindarajan V., de Rivero Vaccari J. P., Keane R. W. Role of inflammasomes in multiple sclerosis and their potential as therapeutic targets. J. Neuroinflammation. 2020 Sep 2;17(1):260. doi: 10.1186/s12974-020-01944-9
- Симанив Т. О., Белкина А. А., Захарова М. Н. Опыт длительного применения интерферонов β в терапии ремиттирующего рассеянного склероза. Consilium Medicum. 2024;26(11):752—8. doi: 10.26442/20751753.2024.11.203057
- Коробко Д. С., Барабанова М. А., Бахтиярова К. З. Долгосрочная терапия рассеянного склероза интерфероном бета-1b. Результаты ретроспективного открытого наблюдательного исследования. Журнал неврологии и психиатрии им. С. С. Корсакова. Спецвыпуски. 2022;122(7-2):96—103. doi: 10.17116/jnevro202212207296
- Рассеянный склероз. Клинические рекомендации. 2024. Режим доступа: https://cr.minzdrav.gov.ru/schema/739_1 (дата обращения 13.09.2025)
- Журавлева М. В., Давыдовская М. В., Лучинина Е. В. Сравнение клинических преимуществ препаратов второй линии, изменяющих течение рассеянного склероза. Журнал неврологии и психиатрии им. С. С. Корсакова. 2020;120(8):148—53. doi: 10.17116/jnevro2020120081148
- Bierhansl L., Hartung H. P., Aktas O. Thinking outside the box: non-canonical targets in multiple sclerosis. Nat. Rev. Drug Discov. 2022;21(8):578—600. doi: 10.1038/s41573-022-00477-5
- Hellwig K., Thiel S., Haben S. Glatiramer acetate or IFN-β bridging therapy in women with relapsing multiple sclerosis planning a pregnancy. Neurodegener. Dis. Manag. 2023;13(4):223—34. doi: 10.2217/nmt-2022-0032
- Kappos L., Edan G., Freedman M. S. BENEFIT and BENEFIT 15 Study Groups. Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial. J. Neurol. 2024;271(7):4599—609. doi: 10.1007/s00415-024-12417-x
- McGinley M. P., Goldschmidt C. H., Rae-Grant A. D. Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA. 2021;325(8):765—79. doi: 10.1001/jama.2020.26858
